Medscape

Relapsing-Remitting Multiple Sclerosis

Insights from AAN 2026, including anticipated presentations, key takeaways, and how emerging research in RRMS may affect ...
Medscape

AAN 2026: Anticipating Updates in Relapsing MS Diagnosis and Treatment

Dr Chu-Yueh Guo prepares to discover how the latest diagnostic criteria and breakthrough treatments are reshaping the ...
Seeking Alpha

Genentech's Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and Primary Progressive MS in Third Positive Phase III Study (FENhance 1)

- FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with ...
Times Argus

Genentech's Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and Primary Progressive MS in Third Positive Phase III Study (FENhance 1)

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the pivotal Phase III study (FENhance 1) of fenebrutinib in RMS met its primary endpoint, showing clinically ...